ArticleJournal of ovarian research2025
A risk prediction model for recurrence in patients with borderline ovarian tumor based on artificial neural network: development and validation study.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEffective management of borderline ovarian tumors (BOTs) requires timely identification of patients at high risk of recurrence. Previous studies suggest that artificial neural networks can improve the prediction of BOT recurrence compared to traditional models, though concerns about their validity persist due to insufficient external validation. We aimed to evaluate the predictive performance of a time-dependent artificial neural network, conduct comprehensive temporal and spatial external validations to address this critical limitation.
methodsClinical data were collected from patients diagnosed with BOT at Shengjing Hospital of China Medical University between January 2014 and August 2023, including 76 cases of recurrence and 584 cases of non-recurrence. Using the Synthetic Minority Oversampling Technique (SMOTE), we balanced the groups at a 1:1 ratio (total sample size, N = 1168). Random sampling was used to divide the data into a training set (70%) and an internal validation set (30%). Temporal (same center; May 2011-December 2013) and spatial (different center; April 2011-April 2019) external validation sets were established. The training set data were input into the input layer of the neural network, high-level features were extracted via neurons in the hidden layer, and the model output was generated from the output layer. The model's sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, time-dependent area under the receiver operating characteristic curve (tdAUC), and integrated Brier score (IBS) were evaluated using the internal validation set, the temporal external validation set, and the spatial external validation set, respectively.
resultsA neural multi-task logistic regression model (N-MTLR) was constructed based on 34 features from the training set after correlation screening, with 9 variables selected for the neural network prediction model. The prediction model consisted of three functional layers with 128, 64, and 32 neurons, respectively, totaling 224 neurons. The optimal parameters for the final model were set as follows: initialization method of glorot_uniform, Dropout rate of 30%, L2 regularization parameter of 1e-2, optimizer of Adam, and learning rate of 1e-4. The N-MTLR model produced higher predictive performance including AUC, accuracy, specificity, PPV and NPV than the Cox-regression model for all survival endpoints at the 2-, the 4- and 7-year time points. Both temporal and spatial external validation results indicated that the model had moderate predictive performance and certain clinical application value.
conclusionsThe N-MTLR neural network enables superior nonlinear modeling of BOT recurrence risk, exhibits excellent temporal and spatial generalizability, which supports precise risk stratification for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.